国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke Registry

第一作者:Tan, Ying

通讯作者:Cnsr Investigators

Minor ischemic stroke acute phase outcomes seconda

基本信息

  • 负责人:Tan, Ying
  • 数据来源: OTHERS
  • 论文编号:OTHERS20190534
  • 发表时间:2017-06-01

2017-06-01

已发表文章

发表杂志:Neurological Research

发表类型: Research Article

影响因子(IF): 2.448

PMID: 28476094 Pubmed原文链接 全文下载

主要研究背景及目的

方法

Patients from the China National Stroke Registry experienced a minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5) and admitted to hospital within 24 hours of symptom onset were included. One-year rates of recurrent stroke, stroke-related disability, and all-cause death were evaluated. Risk factors associated with 1-year stroke recurrence were examined in a multivariate model. The secondary prevention strategies in the acute phase were evaluated as combination of secondary prevention medication classes and the medications used in 1 year follow-up were examined.

结论

Outcomes in individuals in China who had experienced acute minor stroke were unfavorable, underscoring the importance of early, sustained preventive therapy in this patient population. Combination of secondary prevention medication classes was associated with a lower risk of death.

主要结果

The study included 1913 patients who had experienced acute minor ischemic stroke (mean age: 65.1 years; 67.3% men; mean NIHSS score: 2.5). Rates of recurrent stroke, disability, and death were 13.2, 17.0, and 6.3% at 1 year, respectively. History of hypertension, ischemic stroke, transient ischemic attack, and atrial fibrillation were independent predictors of one-year stroke recurrence. Rate of 1 year all-cause death in patients with triple combined therapy in acute phase was 4.1%, whereas in patients with none was 14.5%. At 1 year, only half patients continued the secondary prevention medications.